(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/02002 A1

(51) International Patent Classification[7]: A61K 38/12, 47/26, 9/19

(21) International Application Number: PCT/JP00/04381

(22) International Filing Date: 29 June 2000 (29.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
11/187713 1 July 1999 (01.07.1999) JP

(71) Applicant *(for all designated States except US)*: **FUJISAWA PHARMACEUTICAL CO., LTD.** [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **SAWAI, Seiji** [JP/JP]; 5-3-104, Yashiro-cho, Takarazuka-shi, Hyogo 665-0071 (JP). **KASAI, Akihiro** [JP/JP]; 5-1-2-606, Haginodai, Ikoma-shi, Nara 630-0224 (JP). **OTOMO, Kazumi** [JP/JP]; 11-3, Funaki-cho, Ibaraki-shi, Osaka 567-0828 (JP).

(74) Agent: NOGAWA, Shintaro; Minamimorimachi Park Building, 1-3, Nishitenma 5-chome, Kita-ku, Osaka-shi, Osaka 530-0047 (JP).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*
— *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STABILIZED PHARMACEUTICAL COMPOSITION IN LYOPHILIZED FORM



(I)

(57) Abstract: A stabilized pharmaceutical composition in lyophilized form comprising: a cyclic polypeptide compound represented by general formula (I) wherein R^1 is a hydrogen atom or an acyl group and R^2 and R^3 are, the same or different, a hydrogen atom or a hydroxyl group, or a salt thereof and one or more stabilizer(s) selected from the group consisting of a polysaccharide, a disaccharide and sodium chloride.

WO 01/02002 A1